Physician profile
Donna Smith
NPI 1396744231
$4,589.14
in general payments reported to CMS, 2019-2025
29 companies · $1,281 in 2025
The $1,281 reported for 2025 was more than what 89% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $572 · 2022: $745 · 2023: $879 · 2024: $1,112 · 2025: $1,281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,272.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,335.43 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $504.20 | 2021-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $487.86 | 2022-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $418.11 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Daiichi Sankyo INC. | $268.05 | 2021-2023 | Injectafer |
| Genzyme Corporation | $257.06 | 2023-2025 | |
| Aimmune Therapeutics, INC. | $134.24 | 2024-2025 | Vowst |
| Celgene Corporation | $127.63 | 2022-2023 | Zeposia |
| Nestle Healthcare Nutrition INC. | $120.88 | 2021-2023 | |
| Pfizer INC. | $119.49 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $117.15 | 2024-2025 | Iqirvo, Bylvay |
| Qol Medical, LLC | $110.82 | 2024-2025 | Sucraid, Sucraid |
| Gilead Sciences, INC. | $80.21 | 2021-2023 | |
| Madrigal Pharmaceuticals | $78.65 | 2024-2025 | Rezdiffra, Resmetirom |
| Biofire Diagnostics, LLC | $68.09 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $52.43 | 2023-2024 | Sutab |
| Phathom Pharmaceuticals, INC. | $52.37 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $32.50 | 2023-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $31.49 | 2024-2025 | |
| Lilly USA, LLC | $24.94 | 2025 | Omvoh |
| Medtronic, INC. | $24.10 | 2025 | Gi Genius |
| Novo Nordisk INC | $21.15 | 2025 | Wegovy |
| Organon LLC | $20.64 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $20.21 | 2023 | Dificid |
| Celltrion USA INC. | $19.57 | 2025 | Vegzelma |
| Pharmacosmos Therapeutics INC. | $19.39 | 2021 | |
| Mallinckrodt Hospital Products INC. | $15.03 | 2023 | Terlivaz |
| Phadia US INC. | $14.79 | 2022 | |
| Endogastric Solutions, INC | $12.66 | 2024 | Esophyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.